Generic Medicine Info
Should be taken with food.
Hypersensitivity. Decompensated liver disease. Lactation. Concomitant admin w/ α1-adrenoreceptor antagonist (alfuzosin), analgesics (pethidine, piroxicam, dextropropoxyphene), antiarrhythmics (encainide, amiodarone, bepridil, flecainide, quinidine, propafenone), antihistamines (astemizole and terfenadine), antibacterial (fusidic acid), antipsychotics/neuroleptics (clozapine, pimozide, quetiapine), sedatives and hypnotics (clorazepate, diazepam, estazolam, flurazepam, triazolam, oral midazolam), ergot derivatives (ergotamine, dihydroergotamine, ergonovine, methylergonovine), statins (lovastatin, simvastatin), phosphodiesterase type 5 (PDE5) inhibitors [avanafil, sildenafil (when used for the treatment of pulmonary arterial HTN), vardenafil], GI motility agent (cisapride), voriconazole (ritonavir dose ≥400 mg bid), rifabutin (ritonavir dose of 600 mg bid), St John's wort.
Special Precautions
Patient w/ ischaemic heart disease, cardiomyopathy, pre-existing conduction abnormalities or structural heart disease, haemophilia A or B, porphyria, increased triglycerides. Renal and severe hepatic impairment (Child Pugh Grade C) w/o decompensation. Childn. Pregnancy. Monitoring Parameters Monitor cholesterol, triglycerides, CBC, LFTs, creatine phosphokinase, uric acid,viral load,CD4 count, serum amylase and lipase, glucose.
Adverse Reactions
GI effects (e.g. abdominal pain, nausea, vomiting, diarrhoea, anorexia), asthenia, taste disorder, headache, numbness or tingling around the mouth or extremities, anxiety, insomnia, fever, dizziness, malaise, hyperaesthesia, pharyngitis, rash, pruritus, sweating, vasodilatation, wt loss, allergic reactions (e.g. urticaria, bronchospasm, angioedema, mild skin eruptions); immune reconstitution syndrome, lipodystrophy, osteonecrosis, metabolic abnormalities (e.g. hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia, hyperlactataemia). Reduced levels of Hb, K, free and total thyroxine; increased eosinophil, liver enzymes, amylase and uric acid; reduced or increased WBC and neutrophil counts.
Potentially Fatal: Pancreatitis, hepatic dysfunction, Stevens-Johnson syndrome. Rarely, anaphylaxis.
Drug Interactions
Increases plasma concentrations of budesonide, fluticasone, rivaroxaban. Increased risk of PR interval prolongation w/ (e.g. digoxin, Ca channel blockers, β-blockers, atazanaviation of raltegravir.
CIMS Class
ATC Classification
J05AE03 - ritonavir ; Belongs to the class of protease inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on ritonavir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in